Alnylam Pharmaceuticals (ALNY)

$351.80 +12.69 (3.74%)
Market Cap 44.66B
Revenue (ttm) 2.25B
Net Income (ttm) -278.16M
EPS (ttm) N/A
PE Ratio 1,507.78
Forward PE 47.89
Profit Margin -12.37%
Debt to Equity Ratio 0.00
Volume 2,152,800
Avg Vol 1,523,618
Day's Range N/A - N/A
Shares Out 132.11M
Stochastic %K 43%
Beta 0.32
Analysts Strong Sell
Price Target $491.55

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 551 8200
Fax: 617 551 8101
Address:
675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States
Quantumup
Quantumup Feb. 3 at 7:23 PM
BofA⬆️ $BBIO's PT to $88 from $85 and reiterated at a Buy after providing its thoughts ahead of 4Q earnings. $ALNY $PFE NVO $AZN - IONS $BAYRY Here's what BofA had to say in its note: https://x.com/Quantumup1/status/2018766232087130238?s=20
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 2:36 PM
$ALNY Current Stock Price: $344.54 Contracts to trade: $340.0 ALNY Feb 20 2026 Call Entry: $14.76 Exit: $24.99 ROI: 69% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Arcides
Arcides Jan. 31 at 12:31 AM
$ALNY near that level...
0 · Reply
skeezbag
skeezbag Jan. 30 at 5:26 PM
$ALNY spit the champagne back in the bottle JM and paulbiogeek Cc @johnnygogogo
0 · Reply
anachartanalyst
anachartanalyst Jan. 30 at 1:02 PM
$ALNY https://anachart.com/wp-content/uploads/ana_temp/1769778088_soc-img.jpg
0 · Reply
johnnygogogo
johnnygogogo Jan. 29 at 7:55 PM
$ALNY AlBYElam. Should have gone short when the champagne posts hit. That was over 100 points ago. Lesson learned. Nasdaq problem now. @skeezbag
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 27 at 10:29 PM
$ALNY Share Price: $354.69 Contract Selected: Jul 17, 2026 $350 Calls Buy Zone: $39.44 – $48.72 Target Zone: $67.54 – $82.55 Potential Upside: 62% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
prismmarketview
prismmarketview Jan. 23 at 4:04 PM
Four next‑generation Alzheimer’s drug candidates drawing attention. Biogen’s (NASDAQ: $BIIB), Arrowhead Pharmaceuticals (NASDAQ: $ARWR), Alnylam Pharmaceuticals (NASDAQ: $ALNY), Alector (NASDAQ: $ALEC) All are aiming to move beyond today’s anti‑amyloid antibodies by more precisely targeting tau, amyloid, and neuroinflammation earlier in the disease course.​ https://prismmarketview.com/four-next-generation-alzheimers-drug-candidates-shaping-the-future-of-treatment/
0 · Reply
johnnygogogo
johnnygogogo Jan. 20 at 4:11 PM
$ARWR on what date in the future will Arrowhead have a larger mkt cap than $IONS ? And what future date will they be larger than $ALNY ? Serious and unserious answers welcome.
3 · Reply
jhoffy
jhoffy Jan. 19 at 9:04 PM
$IBRX I would compare this to $ALNY. they were a dollar stock until their products got acceptance and the stock took off. went from $1 to over $100 in a few years. and it kept going higher as their drugs got more and more revenue.
0 · Reply
Latest News on ALNY
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

Jan 29, 2026, 8:00 AM EST - 5 days ago

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 5:16 PM EST - 22 days ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale

Jan 12, 2026, 1:33 PM EST - 22 days ago

Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

Jan 11, 2026, 5:00 PM EST - 23 days ago

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 9:15 AM EST - 4 weeks ago

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 6 weeks ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

AMGN ARGX AZN IBB

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

Dec 17, 2025, 8:00 AM EST - 6 weeks ago

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

Is Alnylam Entering A Corrective Phase After A Strong Run?

Dec 16, 2025, 7:04 AM EST - 7 weeks ago

Is Alnylam Entering A Corrective Phase After A Strong Run?

Walmart was too late for a Nasdaq-100 spot — but these 6 stocks made the cut

Dec 13, 2025, 11:04 AM EST - 7 weeks ago

Walmart was too late for a Nasdaq-100 spot — but these 6 stocks made the cut

WMT FER MPWR STX WDC

Eight stock picks to play one of the healthiest corners of the market

Dec 11, 2025, 10:37 AM EST - 7 weeks ago

Eight stock picks to play one of the healthiest corners of the market

ASND INSM MASI NTRA PODD UNH WGS

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Dec 11, 2025, 7:00 AM EST - 7 weeks ago

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Alnylam Pharmaceuticals Announces Changes to Board of Directors

Dec 3, 2025, 8:00 AM EST - 2 months ago

Alnylam Pharmaceuticals Announces Changes to Board of Directors

CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing

Dec 1, 2025, 3:47 PM EST - 2 months ago

CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing

CRH VRT ARCC

American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades

Nov 30, 2025, 9:23 AM EST - 2 months ago

American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades

CMG FICO GOOG LULU MSFT NFLX ORCL

What's Going On With Alnylam Stock On Friday?

Nov 28, 2025, 12:42 PM EST - 2 months ago

What's Going On With Alnylam Stock On Friday?

Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review

Nov 26, 2025, 1:38 PM EST - 2 months ago

Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review

AFRM AJG ALAB AXON DXCM FICO HOOD

UK's drug-cost watchdog recommends Alnylam's heart disease drug

Nov 20, 2025, 7:09 PM EST - 2 months ago

UK's drug-cost watchdog recommends Alnylam's heart disease drug

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 8:33 AM EST - 2 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 12:41 PM EST - 3 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Nov 8, 2025, 4:57 PM EST - 3 months ago

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors

Nov 5, 2025, 8:10 AM EST - 3 months ago

American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors

AAPL APP CMG GOOGL INSM NFLX STZ

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 3 months ago

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 3 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV AMGN BMY LLY MBX MDGL MEDI

Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak

Oct 31, 2025, 3:58 PM EDT - 3 months ago

Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 2:46 PM EDT - 3 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?

Oct 30, 2025, 2:39 PM EDT - 3 months ago

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Oct 16, 2025, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

Oct 1, 2025, 7:30 AM EDT - 4 months ago

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Sep 28, 2025, 11:13 AM EDT - 4 months ago

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Sep 23, 2025, 2:23 PM EDT - 4 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Sep 18, 2025, 9:15 AM EDT - 4 months ago

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

ILMN

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 5:01 PM EDT - 5 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Sep 9, 2025, 11:16 PM EDT - 5 months ago

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

Sep 8, 2025, 4:15 PM EDT - 5 months ago

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript

Sep 3, 2025, 4:58 PM EDT - 5 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript

Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives

Sep 3, 2025, 12:56 AM EDT - 5 months ago

Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM

Aug 31, 2025, 5:15 AM EDT - 5 months ago

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

Aug 30, 2025, 10:30 AM EDT - 5 months ago

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Aug 30, 2025, 10:30 AM EDT - 5 months ago

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 5 months ago

mRNA Biotechs - Long-Term Value Risks Abound

BNTX DHR GRAL ILMN IONS MRNA RGEN

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Scenic Enters License and Research Agreement with Alnylam

Aug 26, 2025, 5:00 AM EDT - 5 months ago

Scenic Enters License and Research Agreement with Alnylam

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

Aug 11, 2025, 8:00 AM EDT - 6 months ago

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 8:00 AM EDT - 6 months ago

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Aug 1, 2025, 2:28 PM EDT - 6 months ago

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 6 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT AMGN ARGX AZN BAX BIIB

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 6 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT AMGN ARGX AZN BAX BIIB

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:47 PM EDT - 6 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

Jul 31, 2025, 3:36 PM EDT - 6 months ago

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

Quantumup
Quantumup Feb. 3 at 7:23 PM
BofA⬆️ $BBIO's PT to $88 from $85 and reiterated at a Buy after providing its thoughts ahead of 4Q earnings. $ALNY $PFE NVO $AZN - IONS $BAYRY Here's what BofA had to say in its note: https://x.com/Quantumup1/status/2018766232087130238?s=20
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 2:36 PM
$ALNY Current Stock Price: $344.54 Contracts to trade: $340.0 ALNY Feb 20 2026 Call Entry: $14.76 Exit: $24.99 ROI: 69% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Arcides
Arcides Jan. 31 at 12:31 AM
$ALNY near that level...
0 · Reply
skeezbag
skeezbag Jan. 30 at 5:26 PM
$ALNY spit the champagne back in the bottle JM and paulbiogeek Cc @johnnygogogo
0 · Reply
anachartanalyst
anachartanalyst Jan. 30 at 1:02 PM
$ALNY https://anachart.com/wp-content/uploads/ana_temp/1769778088_soc-img.jpg
0 · Reply
johnnygogogo
johnnygogogo Jan. 29 at 7:55 PM
$ALNY AlBYElam. Should have gone short when the champagne posts hit. That was over 100 points ago. Lesson learned. Nasdaq problem now. @skeezbag
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 27 at 10:29 PM
$ALNY Share Price: $354.69 Contract Selected: Jul 17, 2026 $350 Calls Buy Zone: $39.44 – $48.72 Target Zone: $67.54 – $82.55 Potential Upside: 62% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
prismmarketview
prismmarketview Jan. 23 at 4:04 PM
Four next‑generation Alzheimer’s drug candidates drawing attention. Biogen’s (NASDAQ: $BIIB), Arrowhead Pharmaceuticals (NASDAQ: $ARWR), Alnylam Pharmaceuticals (NASDAQ: $ALNY), Alector (NASDAQ: $ALEC) All are aiming to move beyond today’s anti‑amyloid antibodies by more precisely targeting tau, amyloid, and neuroinflammation earlier in the disease course.​ https://prismmarketview.com/four-next-generation-alzheimers-drug-candidates-shaping-the-future-of-treatment/
0 · Reply
johnnygogogo
johnnygogogo Jan. 20 at 4:11 PM
$ARWR on what date in the future will Arrowhead have a larger mkt cap than $IONS ? And what future date will they be larger than $ALNY ? Serious and unserious answers welcome.
3 · Reply
jhoffy
jhoffy Jan. 19 at 9:04 PM
$IBRX I would compare this to $ALNY. they were a dollar stock until their products got acceptance and the stock took off. went from $1 to over $100 in a few years. and it kept going higher as their drugs got more and more revenue.
0 · Reply
Fingerlickengood
Fingerlickengood Jan. 19 at 8:18 PM
$CDXS $ALNY This is pretty interesting! Look who cooperated on this presentation in November and then consider who recently signed EcoSynthesis Evaluation Agreements with Codexis! This could indicate something pretty substantial!!!! https://findresearcher.sdu.dk/ws/portalfiles/portal/160007565/Program.pdf
5 · Reply
SuperGreenToday
SuperGreenToday Jan. 16 at 8:57 PM
$ALNY Share Price: $359.35 Contract Selected: Jun 18, 2026 $350 Calls Buy Zone: $38.34 – $47.36 Target Zone: $66.02 – $80.69 Potential Upside: 63% ROI Time to Expiration: 152 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Fingerlickengood
Fingerlickengood Jan. 15 at 6:22 PM
$CDXS "In March alone, there was a label expansion of Alnylam’s drug Vutrisiran to address ATTR amyloidosis with cardiomyopathy. And Sanofi and Alnylam’s Fitusiran became the seventh siRNA therapeutic to gain FDA approval." Stephen Dilly Q1 2025 Earnings Call $ALNY https://seekingalpha.com/article/4786828-codexis-inc-cdxs-q1-2025-earnings-call-transcript
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 12:14 AM
$ALNY Current Stock Price: $366.81 Contracts to trade: $370 ALNY Jan 16 2026 Call Entry: $2.25 Exit: $4.25 ROI: 89% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
johnnygogogo
johnnygogogo Jan. 14 at 5:37 PM
$ALNY and now another swill of champagne is approx 12 points away from being spit back into the bottle. Obvious chart gap in the $330 area. Convertible debt rollout was the reason the price got so high imo. Then failed indexation attempt with the S&P 500. Sloppy seconds with the Nasdaq 100 (but not a great time to be in the Nasdaq at a low factor). Even their friendship (“payship”) w/ Statnews isn’t helping the current situation. Photo credit to @Pantherfan7979 cc @skeezbag
1 · Reply
wheresdannynow
wheresdannynow Jan. 13 at 9:09 PM
The whole biotech space rose 33.5% in 2025 per IBD, with standouts like $GILD and $ALNY posting big wins
1 · Reply
Davidendz
Davidendz Jan. 13 at 9:01 PM
Biotech sector crushed 2025 with IBD group up 33.5% Big names like $AMGN +25.6%, $GILD +32.9%, and $ALNY +69% leading the charge. This tailwind into 2026 is perfect for DPX platform plays like $BIOV.CSE $BVAXF fresh off strong Jan 8 NMIBC Phase 1 T-cell data.
0 · Reply
VanRamirez937
VanRamirez937 Jan. 13 at 5:51 PM
$ALNY $AEO Mix of growth styles
0 · Reply
Quantumup
Quantumup Jan. 12 at 7:42 PM
TD Cowen reiterated $BBIO Buy; PT 95 $ALNY $PFE $AZN - $IONS NVO Here's what TD Cowen had to say: Attruby Q4 sales of $146MM beat expectations by 9%, leading to an impressive first full year of sales of $362MM. New patient starts surged with an estimated 25% NBRx share, signaling growing market leadership. The late-stage pipeline anchors the next leg of growth, with Phase III wins for LGMD21 and ADH1, while infi's Q1 data could easily support a best-in-class profile — each with $1B+ potential.
0 · Reply
medguy
medguy Jan. 12 at 6:30 PM
Out with small gains $ALNY
0 · Reply
IN0V8
IN0V8 Jan. 12 at 6:16 PM
$ALNY Watch /Buying Opportunity Needham raises target price to $529 from $520
0 · Reply
REDBEAR
REDBEAR Jan. 12 at 5:50 PM
$ALNY technicians, what's a good level to nibble? funnymentalists, what's happening with the company? asking for a friend. thanks.
0 · Reply